Please try another search
For the nine months ended 30 September 2020,Cellular Biomedicine Group Inc revenues decreased 34% to$32K. Net loss increased 13% to $42.1M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Research and development - Balancing val increaseof 10% to $29.1M (expense), General and administrative -Balancing v increase of 23% to $10.5M (expense).
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 0.03 | 0 | 0 | 0.29 |
Gross Profit | 0.02 | 0 | 0 | 0.24 |
Operating Income | -17.69 | -13.37 | -11.43 | -12.8 |
Net Income | -17.04 | -13.53 | -11.55 | -12.69 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 93.09 | 77.57 | 85.89 | 97.32 |
Total Liabilities | 75.76 | 45.04 | 40.74 | 41.61 |
Total Equity | 17.32 | 32.53 | 45.15 | 55.72 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -33.17 | -19.82 | -9.29 | -39.65 |
Cash From Investing Activities | -7.23 | -4.62 | -1.63 | -11.4 |
Cash From Financing Activities | 34.06 | 5.62 | 0.17 | 30.49 |
Net Change in Cash | -6.41 | -18.86 | -10.85 | -20.37 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review